Calyx Appoints Stephen M. Bravo as Chief Medical Officer
March 22, 2021 at 11:55 am
Share
Calyx announced an expansion to its Executive Leadership Team, appointing Dr. Stephen M. Bravo as its Chief Medical Officer (CMO). Dr. Bravo brings more than 30 years of broad experience to Calyx. His expertise stems from having served as a board-certified diagnostic radiologist at highly acclaimed healthcare centers including Brigham and Women's Hospital, as a faculty member at leading academic institutions such as Harvard Medical School, and as a trusted scientific advisor to numerous global pharmaceutical companies. Prior to joining Calyx, he was the Medical Director of Sand Lake Imaging, on the International Scientific Advisory Board for Siemens Medical Corporation's syngo.via, and served as an investigator on over 100 pharmaceutical, non-pharmaceutical, and government-funded research projects.
Cibus, Inc. is an agricultural technology company that uses gene editing technologies to develop plant traits in seeds. Its business is the development of plant traits that help address specific productivity or yield challenges in farming, such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate. It is also engaged in developing, certain alternative plant-based oils or bio-based fermentation products. Its technology is its gene editing platform called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits, four of which are applicable to multiple crops. These traits are PSR in Canola and HT1 and HT3 in rice. In addition, it also has two advanced traits for Sclerotinia resistance and another novel broadleaf HT trait, HT2.
CALYXTPAR 
